Technical Analysis for FPRX - Five Prime Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 5.43 2.45% 0.13
FPRX closed up 2.45 percent on Friday, May 22, 2020, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical FPRX trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Upper Bollinger Band Walk Strength 2.45%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company's product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.
Biotechnology Cancer Life Sciences Solid Tumors Monoclonal Antibodies Tyrosine Kinase Receptors Pfizer Glaxosmithkline Gastric Cancer Inflammatory Disease

Is FPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 8.81
52 Week Low 1.75
Average Volume 328,530
200-Day Moving Average 4.21
50-Day Moving Average 3.07
20-Day Moving Average 3.94
10-Day Moving Average 4.49
Average True Range 0.40
ADX 37.2
+DI 37.27
-DI 6.39
Chandelier Exit (Long, 3 ATRs ) 4.41
Chandelier Exit (Short, 3 ATRs ) 4.00
Upper Bollinger Band 5.37
Lower Bollinger Band 2.50
Percent B (%b) 1.02
BandWidth 72.85
MACD Line 0.56
MACD Signal Line 0.40
MACD Histogram 0.1577
Fundamentals Value
Market Cap 152.47 Million
Num Shares 28.1 Million
EPS -4.26
Price-to-Earnings (P/E) Ratio -1.27
Price-to-Sales 37.28
Price-to-Book 3.79
PEG Ratio 0.14
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.94
Resistance 3 (R3) 5.94 5.77 5.86
Resistance 2 (R2) 5.77 5.64 5.77 5.83
Resistance 1 (R1) 5.60 5.56 5.69 5.60 5.80
Pivot Point 5.43 5.43 5.47 5.43 5.43
Support 1 (S1) 5.26 5.30 5.35 5.26 5.06
Support 2 (S2) 5.09 5.22 5.09 5.03
Support 3 (S3) 4.92 5.09 5.01
Support 4 (S4) 4.92